We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
-2.33%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$244M
AUM Growth
-$11.8M
(-4.6%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
62.11%
Holding
67
New
30
Increased
14
Reduced
7
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$15.1M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$11M |
| 3 |
Guardant Health
GH
|
+$9.53M |
| 4 |
Eli Lilly
LLY
|
+$8.42M |
| 5 |
Edwards Lifesciences
EW
|
+$7.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$15M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$11.3M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$9.3M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$9.06M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$8.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.84% |
| 2 | Consumer Staples | 4.83% |
| 3 | Industrials | 0.1% |
| 4 | Real Estate | 0.04% |
| 5 | Materials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
argenx
ARGX
$53.8B
| $31.3M | 12.84% |
82,735
+46,855
| +131% | +$15.1M |
|
|
2
Eli Lilly
LLY
$1.05T
| $22.6M | 9.25% |
69,667
+28,057
| +67% | +$8.42M |
|
|
3
Edwards Lifesciences
EW
$49.4B
| $17.4M | 7.11% |
182,654
+75,864
| +71% | +$7.85M |
|
4
Stevanato
STVN
$5.23B
| $14.1M | 5.76% |
889,496
+472,576
| +113% | +$7.81M |
|
|
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.5M | 5.54% |
545,532
+249,205
| +84% | +$5.49M |
|
6
SkinHealth Systems
SKIN
$109M
| $11.8M | 4.81% |
914,194
+420,893
| +85% | +$5.64M |
|
|
CTLT
7
DELISTED
CATALENT, INC.
CTLT
| $11.6M | 4.76% |
+108,241
| New | +$11M |
|
|
BLU
8
DELISTED
BELLUS Health Inc.
BLU
| $10.5M | 4.29% |
1,134,408
+124,793
| +12% | +$1.02M |
|
9
Evolent Health
EVH
$654M
| $9.98M | 4.09% |
324,869
+93,370
| +40% | +$2.72M |
|
|
RXDX
10
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $8.97M | 3.67% |
317,758
+168,692
| +113% | +$4.89M |
|
|
11
Jazz Pharmaceuticals
JAZZ
$15.5B
| $8.95M | 3.66% |
57,363
-73,315
| -56% | -$11.3M |
|
|
12
Guardant Health
GH
$20.7B
| $7.76M | 3.18% |
+192,308
| New | +$9.53M |
|
|
TCDA
13
DELISTED
Tricida, Inc. Common Stock
TCDA
| $7.08M | 2.9% |
731,142
+301,759
| +70% | +$2.87M |
|
14
Altimmune
ALT
$558M
| $6.72M | 2.75% |
+574,646
| New | +$3.54M |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.37M | 2.61% |
+111,572
| New | +$6.33M |
|
16
BioNTech
BNTX
$23.1B
| $5.91M | 2.42% |
39,663
+8,740
| +28% | +$1.34M |
|
17
Inspire Medical Systems
INSP
$1.46B
| $5.79M | 2.37% |
+31,705
| New | +$6.32M |
|
|
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.48M | 2.25% |
68,750
-63,582
| -48% | -$6.02M |
|
19
Xenon Pharmaceuticals
XENE
$6.6B
| $5.06M | 2.07% |
+166,399
| New | +$5.03M |
|
|
KZR
20
DELISTED
Kezar Life Sciences
KZR
| $4.17M | 1.71% |
50,434
-22,656
| -31% | -$2M |
|
21
Travere Therapeutics
TVTX
$5.27B
| $3.93M | 1.61% |
+162,014
| New | +$4.07M |
|
22
Celldex Therapeutics
CLDX
$2.77B
| $3.56M | 1.46% |
132,148
-251,171
| -66% | -$7.29M |
|
23
Allogene Therapeutics
ALLO
$618M
| $3.1M | 1.27% |
+272,123
| New | +$2.42M |
|
24
Revolution Medicines
RVMD
$39.6B
| $2.89M | 1.18% |
148,453
-22,002
| -13% | -$428K |
|
25
Coherus Oncology
CHRS
$216M
| $2.73M | 1.12% |
+376,486
| New | +$3.27M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Tri Locum Partners held 67 positions worth $244M, down 4.6% from $256M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Tri Locum Partners deployed $12.7M of net new capital in Q2 2022, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was CATALENT, INC.: 108,241 shares worth $11.6M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Industrials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $11.3M trimmed.
- Tri Locum Partners's largest Q2 2022 buy was CATALENT, INC.: 108,241 shares worth $11.6M.
- Tri Locum Partners added most to argenx in Q2 2022, an estimated $15.1M increase.
- Tri Locum Partners's biggest Q2 2022 reduction was Jazz Pharmaceuticals, cutting an estimated $11.3M.
- Tri Locum Partners fully exited Regeneron Pharmaceuticals in Q2 2022, selling an estimated $15M.
- Tri Locum Partners's ten largest holdings make up 62% of its $244M portfolio in Q2 2022.
- Tri Locum Partners opened 30 new positions and closed 16 in Q2 2022.
- Tri Locum Partners's portfolio value fell 4.6% quarter-over-quarter to $244M.
Based on Tri Locum Partners's 13F filing for Q2 2022, filed 15 Aug 2022.